S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

Mersana Therapeutics Stock Price, News & Analysis (NASDAQ:MRSN)

$1.48
-0.02 (-1.33 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$1.46
Now: $1.48
$1.51
50-Day Range
$1.42
MA: $1.95
$2.66
52-Week Range
$1.40
Now: $1.48
$8.71
Volume202,643 shs
Average Volume239,245 shs
Market Capitalization$70.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.44
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of antibody drug conjugate (ADC) for cancer patients with unmet need. The company develops Dolaflexin, a platform, which is used to generate a pipeline of proprietary ADC product candidates to address patient populations that are not amenable to treat with traditional ADC-based therapies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$10.59 million
Book Value$0.38 per share

Profitability

Net Income$-64,260,000.00

Miscellaneous

Employees86
Market Cap$70.76 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.


Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc (NASDAQ:MRSN) issued its quarterly earnings data on Thursday, August, 8th. The company reported ($0.36) EPS for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.02. The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $1.08 million. Mersana Therapeutics had a negative return on equity of 51.13% and a negative net margin of 77.78%. View Mersana Therapeutics' Earnings History.

When is Mersana Therapeutics' next earnings date?

Mersana Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Mersana Therapeutics.

What price target have analysts set for MRSN?

5 equities research analysts have issued twelve-month target prices for Mersana Therapeutics' stock. Their predictions range from $12.00 to $14.00. On average, they expect Mersana Therapeutics' stock price to reach $13.00 in the next year. This suggests a possible upside of 778.4% from the stock's current price. View Analyst Price Targets for Mersana Therapeutics.

What is the consensus analysts' recommendation for Mersana Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mersana Therapeutics in the last year. There are currently 1 sell rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mersana Therapeutics.

Has Mersana Therapeutics been receiving favorable news coverage?

News stories about MRSN stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Mersana Therapeutics earned a news impact score of -2.8 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Mersana Therapeutics.

Are investors shorting Mersana Therapeutics?

Mersana Therapeutics saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 632,700 shares, a decline of 9.3% from the August 30th total of 697,900 shares. Based on an average daily trading volume, of 239,800 shares, the days-to-cover ratio is presently 2.6 days. Currently, 1.8% of the company's stock are sold short. View Mersana Therapeutics' Current Options Chain.

Who are some of Mersana Therapeutics' key competitors?

What other stocks do shareholders of Mersana Therapeutics own?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 55)
  • Mr. David A. Spellman, Chief Financial Officer (Age 42)
  • Dr. Timothy B. Lowinger, Sr. VP & Chief Scientific Officer (Age 55)
  • Mr. Mikhail Papisov Ph.D., Co-Founder
  • Ms. Sarah Carmody, Exec. Director of Investor Relations & Corp. Communications

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Mersana Therapeutics' major shareholders?

Mersana Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (25.02%). Company insiders that own Mersana Therapeutics stock include Enterprise Associates 14 New and Timothy B Lowinger. View Institutional Ownership Trends for Mersana Therapeutics.

Which major investors are buying Mersana Therapeutics stock?

MRSN stock was bought by a variety of institutional investors in the last quarter, including NEA Management Company LLC. View Insider Buying and Selling for Mersana Therapeutics.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $1.48.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $70.76 million and generates $10.59 million in revenue each year. The company earns $-64,260,000.00 in net income (profit) each year or ($2.79) on an earnings per share basis. Mersana Therapeutics employs 86 workers across the globe.View Additional Information About Mersana Therapeutics.

What is Mersana Therapeutics' official website?

The official website for Mersana Therapeutics is http://www.mersana.com/.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]


MarketBeat Community Rating for Mersana Therapeutics (NASDAQ MRSN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  172 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel